Are you aware of the key developments on the benefit-risk guidelines?

NDAs Steffen Thirstrup, Director NDA Regulatory Advisory Board and Bill Richardson, Pharmacovigilance & Risk Management Expert, have been invited to present at the DIA Workshop on Benefit-Risk Strategy in Hotel Grand Majestic Plaza, Prague 15-16 June.

Professor Thirstrup will chair and Dr Richardson will reflect a number of case studies that clarifies potential risk areas in Session 2: Implementing Benefit-Risk More Effectively.

The session will walk you through the do’s and don’ts of benefit-risk implementation. The essential elements of the session are: – What benefit-risk information to include in the clinical overview – Choosing the right qualitative or quantitative framework.

To read more about the event click here.

 

Steffen-Thirstrup_Blog
Steffen Thirstrup
Bill_Richardsson
Bill Richardson